We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

STRECK LABORATORIES

Develops and manufactures products for clinical and research laboratories in biotechnology, clinical controls, hemato... read more Featured Products: More products

Download Mobile App




New PCR Assay Rapidly Diagnoses Myotonic Dystrophy Gene Targets

By LabMedica International staff writers
Posted on 01 Mar 2015
Print article
Image:  The new real-time PCR PhilisaW Thermal Cycler for faster time-to-results (Photo courtesy of Streck).
Image: The new real-time PCR PhilisaW Thermal Cycler for faster time-to-results (Photo courtesy of Streck).
In a proof-of-principle study, scientists have developed a conventional-PCR diagnostic test that specifically identifies myotonic dystrophy type 1 (DM1) gene targets from whole blood samples in 15 minutes, obviating the need for prior DNA purification or concentration.

Many PCR-based diagnostics are still considered time- and labor-intensive due to disparate purification, amplification, and detection steps. Advancements in PCR enzymes and buffer chemistry have increased inhibitor tolerance, facilitating PCR directly from crude samples. However, direct PCR protocols have also traditionally employed thermal cyclers with slow ramp-rates and conservative hold-times. The objective of the study was to reduce sample preparation and assay time for a PCR-based genetic test by pairing an inhibitor-resistant enzyme mix with a rapid thermal cycler for direct analysis of whole blood samples.

Scientists from Streck, Inc. (Omaha, NE, USA) improved a genetic screening assay of DM1, a triple-repeat genetic disorder and the most common adult form of muscular dystrophy, through adaptation of a conventional PCR by using Streck’s “PhilisaW Thermal Cycler” and New England Biolabs’ inhibitor-resistant “NEB NextW High-Fidelity 2X PCR Master Mix.” Template sample was 10% whole blood. For detection agarose gel electrophoresis or an Agilent 2100 Bioanalyzer was use. As a reference assay, Gene Link’s “Myotonic Dystrophy Genemer Kit” was used per the kit-specific PCR protocol.

PCR amplification of the DM1 short tandem repeats was completed in 15 minutes using 30 cycles, including in situ hot-start/cell lysis. Out of the 40 donors screened, 23 (57.5%) were identified as DM1 negative. These results were 100% concordant with results using the reference kit.

The outcome is a simple exclusionary screening assay for DM1, independent of up-front sample prep, with significant improvement in time-to-results. This approach could also be applied to adapt other conventional PCR tests where genomic DNA is targeted for analysis.

The paper, by Connelly C et al., was published in the December 2014 issue of the journal BMC Medical Genetics.

Related Links:

Streck


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.